Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
The best biotech stocks to buy are in companies that put a lot of resources into research and development, often with nothing to show for it for years. Regulatory hurdles make finding biotech stocks to buy challenging if you don’t have the patience to wait it out. But when biotech companies win approval to sell and marketing a drug, the potential for profits can be off the charts. That’s why it’s a good idea to at least consider biotech, and whether they have a spot in your portfolio.InvestorPla
NEW YORK & LONDON, March 06, 2024--Aptorum Group Limited (Nasdaq: APM), a clinical stage biopharmaceutical company ("Aptorum"), and privately-held YOOV Group Holding Ltd. ("YOOV") jointly announced today that they entered into an Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"). The Merger Agreement was approved by Aptorum’s and YOOV’s boards of directors (each board of directors, the "Board"), respectively. If the Merger Agreement is approved by Apto
NEW YORK & LONDON, December 22, 2023--Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2023.
NEW YORK & LONDON, December 21, 2023--Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, announced the results of its 2023 annual general meeting of shareholders, which was held on December 20, 2023, in London.
NEW YORK & LONDON, November 16, 2023--Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that it will hold its 2023 annual general meeting of shareholders at its London office located at 17 Hanover Square, Mayfair London, England W1S 1BN at 1:00 p.m. London Time on December 20, 2023 (8:00 a.m. Eastern Standard Time on Decem
NEW YORK, August 10, 2023--Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, announced that it has received an approval letter from the Nasdaq Stock Market LLC ("Nasdaq") Listing Qualifications Department notifying the Company it is approved to transfer the listing of its Class A ordinary shares, from the Nasdaq Global Market to the Nasdaq Capital Market. On this basis, the previous two listing deficiencies regarding minimum stockhold
In this piece, we will take a look at ten oversold global stocks to buy. If you want to skip our analysis of the global economic climate, then take a look at 5 Oversold Global Stocks To Buy. Like July, August is full of surprises on the data front. After the U.S. economy grew quite […]
NEW YORK & LONDON & PARIS, June 22, 2023--Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, announced that the group has submitted the relevant Phase 1b/2a clinical trial protocol of SACT-1, an orally administered repurposed small molecule drug for the treatment of neuroblastoma to US FDA. The Phase 1b/2a study of SACT-1 submitted is for the combination with
NEW YORK & LONDON & PARIS, June 09, 2023--Regulatory News: Aptorum Group Limited (the "Company") (NASDAQ:APM, Euronext Paris:APM) announced today that following a comprehensive review of the trading volume, costs and administrative requirements related to its listing on Euronext Paris, it has decided to request the voluntary delisting of its shares (the "Aptorum Shares") (ISIN KYG6096M1226) from Euronext Paris. The Board of Euronext has approved this request.
NEW YORK & LONDON & PARIS, May 05, 2023--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that it has received a letter from the Nasdaq Stock Market LLC ("Nasdaq") Listing Qualifications Department notifying the Company that it is not currently in compliance with the minimum stockhold